HeartSciences Inc.: Form 10-K for the period ended Apr 30, 2023
Filed with the SEC on Jul 19, 2023 and accepted by EDGAR at Jul 18, 2023, 18:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-04-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-05-01 to 2023-04-30 | $5.2k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-05-01 to 2023-04-30 | $2.8k | us-gaap:CostOfRevenue |
| Gross profit | 12 months2022-05-01 to 2023-04-30 | $2.4k | us-gaap:GrossProfit |
| Research and development | 12 months2022-05-01 to 2023-04-30 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2022-05-01 to 2023-04-30 | $3.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-05-01 to 2023-04-30 | −$6.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-05-01 to 2023-04-30 | $243.2k | us-gaap:InterestExpense |
| Net income | 12 months2022-05-01 to 2023-04-30 | −$6.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-05-01 to 2023-04-30 | −$0.80 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-05-01 to 2023-04-30 | −$0.80 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-05-01 to 2023-04-30 | 7,950,550 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-05-01 to 2023-04-30 | −$5.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-05-01 to 2023-04-30 | $18.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-04-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-04-30 | $2.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-04-30 | $3.3m | us-gaap:Assets |
| Current liabilities | At period end2023-04-30 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-04-30 | $3.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-04-30 | $230.6k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-033424. Last ingested by Listed: Nov 2, 2026, 08:01 ET. Listed shows no prices and gives no investment advice.